Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.

Eibich P, Green A, Hattersley AT, Jennison C, Lonergan M, Pearson ER, Gray AM.

Diabetes Ther. 2017 Oct;8(5):1031-1045. doi: 10.1007/s13300-017-0296-x. Epub 2017 Sep 6.

2.

Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients?

Paulino TL, Rafael MN, Hix S, Shigueoka DC, Ajzen SA, Kochi C, Suano-Souza FI, da Silva R, Costa-Carvalho BT, Sarni ROS.

Orphanet J Rare Dis. 2017 Aug 4;12(1):136. doi: 10.1186/s13023-017-0689-y.

3.

The mechanisms of action of metformin.

Rena G, Hardie DG, Pearson ER.

Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. Epub 2017 Aug 3. Review.

4.

The pharmacogenetics of metformin.

Florez JC.

Diabetologia. 2017 Sep;60(9):1648-1655. doi: 10.1007/s00125-017-4335-y. Epub 2017 Aug 3. Review.

PMID:
28770331
5.

Population and allelic variation of A-to-I RNA editing in human transcriptomes.

Park E, Guo J, Shen S, Demirdjian L, Wu YN, Lin L, Xing Y.

Genome Biol. 2017 Jul 28;18(1):143. doi: 10.1186/s13059-017-1270-7.

6.

10 Years of GWAS Discovery: Biology, Function, and Translation.

Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J.

Am J Hum Genet. 2017 Jul 6;101(1):5-22. doi: 10.1016/j.ajhg.2017.06.005. Review.

PMID:
28686856
7.

Mining the Genome for Therapeutic Targets.

Florez JC.

Diabetes. 2017 Jul;66(7):1770-1778. doi: 10.2337/dbi16-0069. Epub 2017 Jun 11.

PMID:
28603140
8.

Personalized medicine: Genetic risk prediction of drug response.

Zhang G, Nebert DW.

Pharmacol Ther. 2017 Jul;175:75-90. doi: 10.1016/j.pharmthera.2017.02.036. Epub 2017 Feb 14. Review. Erratum in: Pharmacol Ther. 2017 Dec 10;:.

PMID:
28213088
9.

Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users.

Luciano-Mateo F, Hernández-Aguilera A, Cabre N, Camps J, Fernández-Arroyo S, Lopez-Miranda J, Menendez JA, Joven J.

Nutrients. 2017 Feb 10;9(2). pii: E121. doi: 10.3390/nu9020121. Review.

10.

The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.

Floyd JS, Psaty BM.

Diabetes Care. 2016 Nov;39(11):1858-1869.

11.

Genomic Characterization of Metformin Hepatic Response.

Luizon MR, Eckalbar WL, Wang Y, Jones SL, Smith RP, Laurance M, Lin L, Gallins PJ, Etheridge AS, Wright F, Zhou Y, Molony C, Innocenti F, Yee SW, Giacomini KM, Ahituv N.

PLoS Genet. 2016 Nov 30;12(11):e1006449. doi: 10.1371/journal.pgen.1006449. eCollection 2016 Nov.

12.

The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug.

Sacco F, Calderone A, Castagnoli L, Cesareni G.

Br J Cancer. 2016 Dec 6;115(12):1451-1456. doi: 10.1038/bjc.2016.385. Epub 2016 Nov 22. Review.

13.

The role of the p53 tumor suppressor in metabolism and diabetes.

Kung CP, Murphy ME.

J Endocrinol. 2016 Nov;231(2):R61-R75. Epub 2016 Sep 9. Review.

14.

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.

Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L; MetGen Investigators; DPP Investigators; ACCORD Investigators, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER.

Nat Genet. 2016 Sep;48(9):1055-1059. doi: 10.1038/ng.3632. Epub 2016 Aug 8.

15.

Leveraging Genetics to Advance Type 2 Diabetes Prevention.

Florez JC.

PLoS Med. 2016 Jul 26;13(7):e1002102. doi: 10.1371/journal.pmed.1002102. eCollection 2016 Jul.

16.

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.

Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic RM.

Clin Pharmacol Ther. 2016 Nov;100(5):537-547. doi: 10.1002/cpt.428. Epub 2016 Sep 23.

17.

Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.

Sam WJ, Roza O, Hon YY, Alfaro RM, Calis KA, Reynolds JC, Yanovski JA.

J Clin Pharmacol. 2017 Feb;57(2):219-229. doi: 10.1002/jcph.796. Epub 2016 Aug 23.

18.

Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.

Shokri F, Ghaedi H, Ghafouri Fard S, Movafagh A, Abediankenari S, Mahrooz A, Kashi Z, Omrani MD.

Int J Mol Cell Med. 2016 Winter;5(1):1-7.

19.

A Genome-Wide Association Study Provides New Evidence That CACNA1C Gene is Associated With Diabetic Cataract.

Chang C, Zhang K, Veluchamy A, Hébert HL, Looker HC, Colhoun HM, Palmer CN, Meng W.

Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2246-50. doi: 10.1167/iovs.16-19332.

20.

Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.

Staiger H, Schaeffeler E, Schwab M, Häring HU.

Rev Diabet Stud. 2015 Fall-Winter;12(3-4):363-76. doi: 10.1900/RDS.2015.12.363. Epub 2016 Feb 10.

Supplemental Content

Support Center